Form 4: BioCryst Pharmaceuticals Director Alan G. Levin Reports Transaction
SEC Form 4 Filing
Director Alan G. Levin of BioCryst Pharmaceuticals Inc. reports the acquisition of 7,861 shares of common stock at $6.36 per share on May 30, 2024.
Summary
- On May 30, 2024, Alan G. Levin, a director of BioCryst Pharmaceuticals Inc., acquired 7,861 shares of common stock.
- The purchase price was $6.36 per share.
- Following the transaction, Levin directly owns 44,951 shares of BioCryst Pharmaceuticals Inc.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. A director purchasing shares suggests confidence, but it's a single transaction and doesn't provide a comprehensive view.
Positives
- A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.
Industry Context
Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge sentiment and potential future performance.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 05/30/2024 | Date of transaction: Alan G. Levin acquired shares of BioCryst Pharmaceuticals Inc. |
| 05/31/2024 | Date of signature on the report. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.